CXCR1 and type 1 diabetes mellitus: Indeed, based on our encouraging preclinical data on the role of CXCR1/2 inhibition in NOD mice (52), we investigated the role of ladarixin, a CXCR1/2 inhibitor, in the preservation of β cell function and slow-down of the progression of T1D in a phase II, multicenter, double-blind study that involved 76 patients with new-onset (NCT02814838).